JP Morgan Chase’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-2,200
Closed -$56K 6875
2021
Q3
$56K Buy
+2,200
New +$65.2K ﹤0.01% 5802

Other funds holding PACB

JP Morgan Chase's PACB Position: Q2 2026 in Review

JP Morgan Chase increased its Pacific Biosciences (PACB) stake by 5.4% in Q2 2026, buying an estimated $10.8K and bringing the position to 145,948 shares worth $252K. The position accounts for ﹤0.01% of the portfolio, ranked #5498.

JP Morgan Chase first reported a position in PACB in Q2 2013 and has held it in 48 quarters since. The position peaked at $19.6M in Q1 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • JP Morgan Chase held 145,948 shares of Pacific Biosciences worth $252K as of Q2 2026.
  • JP Morgan Chase bought 7,444 Pacific Biosciences shares in Q2 2026, an estimated $10.8K.
  • Pacific Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5498 holding.
  • JP Morgan Chase first reported a position in Pacific Biosciences in Q2 2013 and has held it in 48 quarters since.
  • JP Morgan Chase's Pacific Biosciences position peaked at $19.6M in Q1 2021.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.